Safety, Tolerability, and Pharmacokinetics of the Anti-Igf-1r Monoclonal Antibody Figitumumab in Patients With Refractory Adrenocortical Carcinoma

Cancer Chemotherapy and Pharmacology - Germany
doi 10.1007/s00280-009-1083-9

Related search